Why is Pfizer falling/rising?

As of 22-Sep, Pfizer Ltd. is experiencing a decline in its stock price, currently at 5,070.00, which reflects a decrease of 40.05 or 0.78%. The stock has been underperforming recently, with a consecutive fall over the last three days resulting in a total drop of 2.53%. While the stock has outperformed its sector by 0.3% today, it has shown negative returns over various periods, including a 10.48% decline over the past month and a 3.50% drop year-to-date. Despite these challenges, the company boasts a high management efficiency with a return on equity (ROE) of 18.22% and a low debt-to-equity ratio, which may provide some stability amidst the current downturn.
In the broader market context, Pfizer's recent performance contrasts sharply with the benchmark Sensex, which has gained 0.46% over the past week and 1.05% over the past month. This indicates that while the market is generally trending upward, Pfizer is lagging behind. The stock's liquidity remains adequate, and there has been a notable increase in investor participation, with delivery volume rising by 73.85% against the five-day average. However, the overall negative return trends and the stock's position below several moving averages suggest that investor sentiment may be cautious, contributing to the stock's recent decline.